Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was incorporated in 2020 and is based in Camberwell, Australia.
| Market Capitalization | $6.3389 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.036 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.04 |
| EBITDA | |
| Profit Margin | 0 |
| Operating Margin TTM | -770.2365 |
| Return on Assets TTM | -0.4623 |
| Return on Equity TTM | -0.7746 |
| Revenue TTM | 4.559 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2019-12-31 | 0 | |||
| 2020-12-31 | 0 | 2,138.943 | ||
| 2021-12-31 | 0 | 2,809.005 | ||
| 2022-12-31 | 11.07 | 11.065 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2019-12-31 | 0 | 0.02 | 0.67 | 0 | 0.001 | |
| 2020-12-31 | 6,460.644 | 6,635.91 | 236.83 | 0 | 19,825.792 | |
| 2021-12-31 | 4,787.437 | 4,898.876 | 580.733 | 0 | 19,900.792 | |
| 2022-12-31 | 1,998.26 | 2,049.22 | 263.85 | 0 | 19,900.79 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2019-12-31 | -0.658 | -938.235 | 6,460.643 | 0.001 | ||
| 2020-12-31 | -2,126.754 | -938.235 | 6,460.643 | 0.001 | 6,460.644 | |
| 2021-12-31 | -2,606.887 | -1,877.638 | -1,673.207 | 6,460.644 | 4,787.437 | |
| 2022-12-31 | -2,830.449 | -2,699.76 | -2,789.17 | 4,787.437 | 1,998.263 |